ProCE Banner Series

Refining Approaches to Overcome Challenges, Enhance Consistency, and Standardize Scoring and Reporting in HER2-Expressing Solid Tumors

Join us either in-person or online for this interactive symposium in conjunction with USCAP 2025 in which a panel of pathologists and medical oncologists will discuss the nuances of HER2 testing across GI, lung, and other solid tumors and the impact of testing results on treatment selection.

To register for the in-person meeting, please register here: https://2025am.uscap.org/

  AMA
Who Should Attend

This educational program is intended for pathologists, oncologists, and other healthcare professionals in the precision care of HER2-altered solid tumors.

All Events

Refining Approaches to Overcome Challenges, Enhance Consistency, and Standardize Scoring and Reporting in HER2-Expressing Solid Tumors

Upcoming Events

March

26

2025

6:30 AM - 7:30 AM Eastern Time (ET)

Virtual

Boston Convention and Exhibition Center, 415 Summer St., Boston, Massachusetts 02210

Topics

Gastrointestinal cancer, lung cancer

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners' knowledge, confidence, and competence in accurately performing pathological assessment, diagnosing, and reporting results to provide evidence-based treatment strategies for patients with HER2-altered solid tumors.

Target Audience
This educational program is intended for pathologists, oncologists, and other healthcare professionals in the precision care of HER2-altered solid tumors.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Implement pathological procedures to consistently and accurately identify patients who may benefit from HER2-targeted therapy through a proper understanding of HER2 status across solid tumors and the use of guideline and expert-recommended testing
  • Summarize the importance of proper HER2 evaluation through consideration of current and emerging clinical trial data and recent FDA-approved indications to inform patient care
  • Identify barriers to pathological assessment and implement approaches to standardize HER2 scoring and reporting in clinical practice
  • Collaborate with the multidisciplinary team to optimize therapeutic strategies for patients with HER2-altered solid tumors

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1. MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

American Board of Pathology Continuing Certification

A blue and white microscopeDescription automatically generated with low confidence

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning point in the American Board of Pathology’s Continuing Certification Program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit. 

For ABPath Lifelong Learning points, your information will be shared with the ABPath through CCO’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your Lifelong Learning points to appear on your ABPath records. 

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals.